Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006;8 Suppl 2(Suppl 2):S48-55.

The treatment of hormone-refractory prostate cancer: docetaxel and beyond

Daniel P Petrylak

The treatment of hormone-refractory prostate cancer: docetaxel and beyond

Daniel P Petrylak. Rev Urol. 2006.

Abstract

Two randomized clinical trials demonstrated a survival benefit of 20% to 24% with docetaxel-based therapy when compared with survival with mitoxantrone and prednisone after failure of androgen ablation therapy. These studies supported the approval of docetaxel-based therapy for the treatment of metastatic hormone-refractory prostate cancer by the US Food and Drug Administration in May 2005. Clinical trials in hormone-refractory prostate cancer are now focused on building on the survival improvement seen with docetaxel-based therapy. This article presents a summary of some of the more promising treatments and regimens for advanced prostate cancer.

PubMed Disclaimer

References

    1. Petrylak DP. Chemotherapy for androgen-independent prostate cancer. Semin Urol Oncol. 2002;20:31–35. - PubMed
    1. Nelson J, Bagnato A, Battistini B, et al. The endothelin axis: emerging role in cancer. Nat Rev Cancer. 2003;3:110–116. - PubMed
    1. Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol. 2003;21:679–689. - PubMed
    1. Vogelzang N, Nelson J, Schulman C, et al. Meta-analysis of clinical trials of atrasentan 10 mg in metastatic hormone-refractory prostate cancer. Proc Am Soc Clin Oncol. 2005;23:393S.
    1. Hussain M, Tangen CM, Lara PN, Jr, et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol. 2005;23:8724–8729. - PubMed

LinkOut - more resources